| Subject: | FDA Issues Notification About Revised Warnings With Use of Humira and Anakinra |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 9 Nov 2004 - 10:00 am |
| The FDA and Abbott Pharmaceuticals have issued a warning to healthcare professionals about the use of Humira (adalimumab), a TNF - blocking agent and Kineret (anakinra) a selective blocker of interleukin-1, both of which are used in the treatment of rheumatoid arthritis. The FDA notes that the warnings on these drugs have been revised to include the following when the drugs are used in combination (a TNF-blocking agent used with Kineret):
Serious... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
